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Introduction 
 
Tocolysis is one of the greatest challenges in obstetrical practice. Despite research 
directed to the development of drugs to inhibit myometrial contractions, there has been no 
reduction in the incidence of PTB for more than 30 years. A number of agents are used 
clinically as tocolytics, but the efficacy of the current modes of pharmacological treatment 
has been questioned. 
In recent years, Ca2+ channel antagonists have been used increasingly as tocolytic 
agents. These agents act to inhibit Ca2+ influx across the cell membrane, thereby 
decreasing the tone in the smooth muscle vasculature. The dihydropyridines are the most 
potent inhibitors of uterine tension development among the Ca2+ entry blockers and are 
therefore of considerable interest for both therapeutic and experimental purposes. 
Nifedipine and its analogs have recently been considered as tools for tocolytic therapy. 
With a view to decreasing the potentially maternal and foetal adverse events and 
improving the perinatal outcome, there is growing interest in experimental studies of the 
possible use of different tocolytic combinations.  
 
Aims 
 
The main focus of our study was to enhance the tocolytic effect of nifedipine. Since no 
extensive experiments have been carried out to investigate the in vivo and in vitro uterus-
relaxing effect of a combination of nifedipine and β2-mimetics or progesterone in the rat 
and also on human myometrium, the following aims were set: 
1. The first aim of the study was to investigate the effects of nifedipine on the potassium 
chloride (KCl)-evoked rat uterine contractions on different days (15, 18, 20, and 22) 
of pregnancy in vitro.  
2. Our further aim was to alter the effect of nifedipine on rat myometrium by applying a 
combination with terbutaline, progesterone or BKCa-channel inhibitors, which can 
have effects on the Cav1.2 channel. 
3. The efficacy of the Cav1.2 channel blocker – β2-agonist combination has not been 
investigated on isolated human myometrium. In our study we investigate how 
terbutaline and nifedipine modify the contractions of the isolated human 
myometrium.  
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4. And finally, our last aim was to investigate the effects of nifedipine – salmeterol and 
nifedipine – progesterone combination in hormone-induced PTB model in vivo, 
whether these drug interactions apply under in vivo circumstances.  
 
Materials and methods 
 
Mature female (180-200 g) and male (240-260 g) Sprague-Dawley rats were mated 
in a special mating cage. Vaginal smears were taken from the female rats and a sperm 
search was performed under a microscope at a magnification of 1200 x. When the smear 
provided positive, the female rats were separated as first-day pregnant animals. 
  
In vitro studies 
 
Uterus preparation, investigation the effect of nifedipine on rats’ myometrium 
 
Uteri were removed from rats on day 15, 18, 20 or 22 of pregnancy. Muscle rings 5 mm 
long were sliced from the uterine horns and mounted vertically in an organ bath containing 
10 ml de Jongh solution, which was maintained at 37 °C and carbogen was bubbled 
through it. Contractions were elicited with 25 mM or 100 mM KCl, and noncumulative 
dose–response curves were constructed in each experiment in the presence of nifedipine 
(10-11–10-6 M). Concentration–response curves were fitted, and areas under curves (AUCs) 
were evaluated and analyzed statistically with the Prism 4.0 computer program. For 
statistical evaluations, data were analyzed by the ANOVA Neuman-Keuls test. . 
 
Investigation the effect of BKCa-channel blockers on nifedipine action 
 
Uteri were removed from rats on day 22 of pregnancy and mounted vertically in the organ 
bath as described above. Contractions were elicited with 10-6 M oxytocin and cumulative 
nifedipine (10-11 – 10-6 M) dose-response curves were constructed in each experiment in 
the presence of paxilline (5 µM) or TEA (10-3 M). For statistical evaluations, data were 
analyzed by the ANOVA Neuman-Keuls test. 
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Nifedipine combination with terbutaline 
 
Uteri were removed from rats on day 22 of pregnancy and mounted vertically in the organ 
bath as described above. Contractions were elicited with 25 mM KCl, and non-cumulative 
dose–response curves were constructed in each experiment in the presence of nifedipine 
(10-11–10-6 M) and terbutaline (10-7 M) or terbutaline (10-10–10-4 M) and nifedipine (10-7 
M). The effects of the nifedipine – terbutaline combination were also investigated in the 
absence of Ca2+ ion in vitro. De Jongh solution containing 0.5 mM Ca2+ ion was used to 
induce a low Ca2+ environment. After the equilibration period, the normal De Joung 
solution was changed to the low Ca2+-containing solution. The Emax and EC50 values of the 
curves obtained with the combinations were calculated. For statistical evaluations, data 
were analyzed through the unpaired t test. 
 
In vivo studies 
 
Induction of preterm labour 
 
The animals were treated with mifepristone (3 mg per 0.1 ml) and PGE2 (0.5 mg/animal) 
on day 19 of pregnancy. Mifepristone was suspended in olive oil and given as a 
subcutaneous injection at 9:00 A.M. At 4:00 P.M, PGE2 was applied intravaginally. The 
delivery time of the first foetus was noted as the duration in hours from the time of 
mifepristone administration. 
 
Treatments of the animals 
 
Alzet osmotic pumps were loaded with nifedipine, salmeterol xinofoate solution or vehicle. 
In combination studies two different osmotic pumps were inserted subcutaneously into the 
back skin of rats on days 16 or 18 of pregnancy under isoflurane anesthesia. The 
progesterone treatment of the pregnant animals was started on day 15 of pregnancy and 
was injected subcutaneously every day up to delivery (days 19 or 20).  
Group A was the control group, while group B was treated with vehicle, group C with 
nifedipine, group D with the nifedipine–salmeterol combination and group E with the 
nifedipine–P4 combination. There were 8 rats in each group. Statistical analyses were 
carried out with the analysis of Dunnett's Multiple Comparison Test. 
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Human myometrial studies 
 
Biopsy specimens of human myometrial tissue were obtained at caesarean section in the 
third trimester of pregnancy. Uterine smooth muscle tissue samples were collected at 37 to 
40 weeks of gestation.  
Longitudinal myometrial strips were mounted vertically in an organ bath containing Krebs-
Henseleit solution. The organ bath was maintained at 37 °C and carbogen was bubbled 
through it. After eliciting contractions with 10-6 M oxytocin, noncumulative dose–response 
curves were constructed in each experiment with nifedipine (10-11–10-5 M) and terbutaline 
(10-7 M) or terbutaline (10-11–10-5 M) and nifedipine (10-7 M). Concentrations-response 
curves were fitted, and areas under curves (AUCs) were evaluated. For statistical 
evaluations, data were analyzed by use of the unpaired t test. 
 
Results 
 
Animal studies 
 
Organ bath studies 
 
The 25 mM and 100 mM KCl-stimulated uterine contractions were inhibited 
concentration-dependently by nifedipine in the range of 10-11−10-6 M (Fig. 1).  
The presence of selective or non-selective BKCa-channel inhibitors (paxilline or TEA) had 
no effect on the maximal relaxing effect of nifedipine and did not modify the EC50 values 
of nifedipine. Although, paxilline shifted the nifedipine curve to the left, but it was not 
significant. 
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Fig. 1: Contraction inhibiting effect of nifedipine on isolated pregnant rat uteri evoked by 100 mM (a)  
and 25 mM (b) potassium chloride in vitro on different days of pregnancy. (• day 15, day 18,  day 20, € 
day 22). 
 
The concentration–response curves for nifedipine in the presence of 10-7 M terbutaline 
were shifted to the left and a decrease in the maximal inhibitory effect was observed. In the 
presence of 0.5 mM Ca2+ (Ca2+-poor buffer), terbutaline did not alter the effect of 
nifedipine. 
The concentration–response curves for terbutaline in the presence of 10-7 M nifedipine 
were also shifted to the left, but this shift was greater than that of the nifedipine curve by 
terbutaline. Nifedipine also significantly increased the Emax of terbutaline. In the Ca2+-poor 
buffer, the presence of nifedipine increased the EC50 of terbutaline, but did not alter its 
Emax.   
 
In vivo studies 
 
In group A (control), preterm labour occurred within 24 hours after mifepristone treatment, 
at about 9:00 a.m. on pregnancy day 20. The vehicle (group B) did not alter the time of 
delivery relative to that in group A. 
Nifedipine (group C) treatment started on pregnancy day 16 was effective in delaying the 
hormone-induced preterm delivery by 6.6 hours. In group D (nifedipine–salmeterol 
combination), the treatment was extremely effective; preterm birth was delayed by ~ 24 
hours as compared with group A.  
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When started on day 18 of pregnancy (Fig. 2a.), nifedipine treatment (group C) was not 
effective. In contrast in group D (combination therapy) the treatment was effective; labour 
was delayed by ~ 25 hours. The difference in efficacy between groups C and D was most 
expressed for the treatment started on day 18.  
With the nifedipine – P4 combination (Fig. 2b.), the P4 pre-treatment (group E) abolished 
the effect of nifedipine (group C).  
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Fig. 6: The effects of treatment with nifedipine (3.89 mg/day) or the nifedipine – salmeterol combination (a) 
and nifedipine – progesterone (b) on hormone-induced preterm delivery in the rat (n = 8 for each group). 
Treatment was started on gestation day 16. 
A: control group; B: vehicle-treated (PEG400 : ethanol : physiological salt solution = 6:6:4 + methanol : 
water =1:1 in osmotic minipump); C: nifedipine-treated; D: nifedipine – salmeterol combination-treated; E:  
nifedipine – progesterone treated animals. 
The bar graphs show means ± SD. The effects were compared with the results on group A. 
ns: not significant; *: p<0.05; ***: p<0.001. 
 
Human myometrial studies 
 
The 10-6 M oxytocin-stimulated human uterine contractions were inhibited concentration-
dependently by nifedipine and terbutaline in the range 10-5−10-11 M (Fig. 3. a, b). The 
addition of 10-7 M terbutaline to nifedipine did not alter the Emax of nifedipine, but 
decreased EC50 from 1.8 x 10-8 M to 1.5 x 10-6 M (p<0.05) (Fig. 3a). The addition of 10-7 
M nifedipine to terbutaline increased the Emax of terbutaline (Fig. 3b), from 60.8% to 76.8 
% (p<0.01) but EC50 was not changed. 
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Fig. 3: The effects of treatment with the nifedipine – terbutaline combination on oxytocin-evoked human 
myometrial contractions in vitro. 
a: ■ nifedipine (10-11-10-5 M); ● terbutaline (10-7 M) + nifedipine (10-11-10-5 M) 
b: ■ terbutaline (10-11-10-5 M); ● nifedipine (10-7 M) + terbutaline (10-11-10-5 M 
 
Discussion 
 
The most important factor controlling force in the myometrium is the concentration of 
intracellular Ca2+, and membrane potential is the major factor governing Ca2+ entry into the 
cell. In the presence of 25 mM KCl the uterine contractions were rhythmic and the relaxing 
effect of nifedipine was the highest on the last day of pregnancy. These results led us to 
conclude that stimulation with 25 mM KCl is much more appropriate for investigations of 
the action of the Ca2+ channel blocker nifedipine. As the relaxing effect of nifedipine was 
highest on the last day of pregnancy, further experiments were carried out on day 22. 
The activity of the Cav1.2 channel is regulated by several factors. The studies with the 
selective BKCa channel blocker paxilline and non-selective blocker TEA were carried out 
by oxytocin-induced contractions, because in these cases the stimulation with KCl was not 
useful. The results revealed that BKCa channels and any other K+ channels are not involved 
in the relaxing effect of nifedipine in pregnant rat myometrium.  
Progesterone is regarded as a preventive drug against PTB, especially in late-preterm birth. 
Unfortunately, the in vivo progsterone pre-treatment decreased the maximal inhibitory 
effect of nifedipine and increased its EC50.  
 9  
 
 
The other investigated factor which regulates the Cav1.2 channel was the β2-adrenergic 
system. We found synergism in the uterus-relaxing effect of nifedipine and the β2-AR 
agonist terbutaline, although the extent of potentiation depended on the sequence of 
administration of the two compounds. When terbutaline was added first in a single dose, 
synergism was found in EC50 (the nifedipine curve was shifted to the left), but the maximal 
inhibitory effect of nifedipine was lower. When nifedipine was administered first, the 
relaxing effect of terbutaline was obviously stronger. 
The entry of the Ca2+ into the cells through the voltage-gated Ca2+ channel is one of the 
crucial factors in the generation of smooth muscle contraction. Terbutaline possibly 
activates the Cav1.2 channels and decreases the maximal relaxing effect of nifedipine. The 
resultant effect of the increase of cAMP level and activation of Cav1.2 channels causes a 
weaker smooth muscle relaxation. In the opposite case, when nifedipine is administered 
first, the Cav1.2 channels are blocked; hence, there is only a low possibility that terbutaline 
can activate them.  
To check on the above-mentioned hypothesis, the synergism between the two compounds 
was investigated in Ca2+-poor buffer. A Ca2+-poor environment theoretically decreases the 
terbutaline-induced Ca2+ influx and may alter the extent of the synergism. The Ca2+-poor 
environment shifted the nifedipine dose-response curve to the left, and the maximal 
inhibitory effect of nifedipine was so high that its effect could not be enhanced by 
terbutaline. In contrast, the Ca2+-poor environment shifted the terbutaline dose-response 
curve to the left, but nifedipine was able to enhance the shift. However, it could not 
increase the maximal uterus-relaxing effect of terbutaline, possibly because of the very 
strong blocking effect of the β-mimetic. These results indicate that, in a Ca2+-poor 
environment, terbutaline is not able to worsen the maximal effect of nifedipine, which 
suggests the role of the Ca2+ inflow in the weakening effect of terbutaline. 
Synergism between nifedipine and the β2-agonist terbutaline was also investigated on 
human myometrium tissue, which revealed that both nifedipine and terbutaline inhibit the 
oxytocin-induced myometrial contractions dose-dependently. When terbutaline was added 
first, it decreased the EC50 of nifedipine, though it did not alter the Emax of nifedipine. In 
the opposite case, nifedipine administered first increased the relaxing effect of terbutaline, 
though there was no difference in EC50. The results suggest a parallelism between the 
human situation and that in the rat myometrium. 
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In view of these results, the effects of nifedipine – salmeterol and nifedipine – 
progesterone combination were investigated also in hormone-induced PTB model in vivo, 
whether these drug interactions apply under in vivo circumstances. We found that 
treatment with nifedipine alone started on pregnancy day 16 was more effective in 
delaying delivery than salmeterol treatment alone. Similarly, the nifedipine − salmeterol 
combination also had a great effect. 
The short-term effects of nifedipine and its combination with salmeterol were also tested in 
our experiments. Nifedipine treatment started on day 18 did not delay labour, but the 
nifedipine − salmeterol combination was as effective as the combination started on the 
pregnancy day 16. The ability of nifedipine to delay labour was tripled by its combination 
with the β2-agonist. In our in vivo study two osmotic pumps were implanted 
subcutaneously in the rat and the administration of the two agents was simultaneous and 
continuous. The results suggested that the parallel administration of the two compounds 
may lead to a similar benefit as that of nifedipine-potentiated terbutaline treatment.  
Progesterone pre-treatment also abolished the ability of nifedipine to delay labour in 
hormone-induced preterm delivery in rats in vivo. These results correlate with the 
hypothesis that progesterone decreases the activity of the L-type Ca2+ channels. 
In the light of our results, we can conclude that progesterone pre-treatment abolished the 
ability of nifedipine to delay labour in hormone-induced preterm delivery in rat. These 
results correlate with the hypothesis that progesterone decreases the activity of the L-type 
Ca2+ channels. 
There is growing interest in nifedipine as a potentially effective and well-tolerated form of 
tocolysis. Nifedipine has been demonstrated to have fewer side-effects and leads to a better 
neonatal outcome than β2-mimetics. We presume that the effect of nifedipine in tocolytic 
therapy might be intensified through combination with β2-adrenerg agonists and enhanced 
by low concentrations of β2-mimetics. However, our results indicate that the administration 
of β2-adrenergic agonists can not precede that of nifedipine. The significance of these 
experimental findings remains to be validated in clinical trials, including human side 
effects. 
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